Generated August 8, 2026.
Overview
IBB and XBI are both biotechnology-focused ETFs that track US-listed biotech companies, but they differ in their index construction and volatility profile. IBB tracks the ICE Biotechnology Index with market-cap weighting and has been around since 2001, while XBI tracks the S&P Biotechnology Select Industry Index using equal-weight methodology and launched in 2006. The equal-weight approach in XBI tilts exposure toward smaller holdings and amplifies price swings relative to the broader biotech sector.
How they differ
The most important structural difference is index methodology: IBB uses market-cap weighting, concentrating exposure in the sector's largest companies, while XBI employs equal weighting, which automatically overweights smaller constituents and rebalances more frequently. That difference shows up directly in beta — XBI's 1.1 is notably higher than IBB's 0.69, meaning XBI amplifies both upswings and downswings in biotech performance. On cost, XBI has a slight edge with a 0.35% expense ratio versus IBB's 0.45%, and they're nearly identical on yield (0.05% for IBB, 0.07% for XBI). AUM is similar in both — IBB holds $9.31B and XBI $9.96B — so liquidity shouldn't be a concern with either.
Who each is best for
IBB: Fits investors seeking a lower-volatility biotech exposure that tracks the sector's largest and most established players, with stability closer to the broader market than individual biotech holdings would offer.
XBI: Designed for investors comfortable with higher price swings who want more balanced exposure across the biotech index, including smaller-cap names that market-cap weighting would de-emphasize.
Key risks to know
- Index methodology risk. XBI's equal-weight approach concentrates capital in smaller, typically less-liquid biotech names relative to market-cap weighting. This creates rebalancing drag and higher turnover costs that may not show up fully in the stated expense ratio.
- Beta divergence and sector timing. XBI's beta of 1.1 versus IBB's 0.69 means drawdowns in biotech will hit XBI roughly 60% harder — a material gap for investors uncomfortable with amplified swings. Conversely, strong sector rallies will favor XBI.
- Concentration overlap. Both track the same underlying sector with similar large-cap holdings, so their performance will be correlated despite different weightings. Holding both offers minimal incremental diversification benefit.
- Clinical trial and regulatory risk. As pure-play biotech baskets, both are heavily exposed to FDA approval outcomes, clinical trial results, and patent-cliff risk across their holdings — idiosyncratic risks that equity markets cannot fully price in advance.
Bottom line
If you value stability and lower volatility, IBB's market-cap weighting and beta of 0.69 provide a steadier ride through biotech cycles. If you're willing to tolerate bigger swings and want broader exposure across the index including smaller players, XBI's equal-weight approach and lower expense ratio offer that tradeoff — though you're paying for it with higher market sensitivity. Past performance doesn't predict future results, and both carry concentrated sector risk regardless of weighting.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
